Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 310
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02226146 | Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid | ||
| NCT06607627 | PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | ||
| NCT02104219 | Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP) | ||
| NCT07308574 | Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS | ||
| NCT06398158 | Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder | ||
| NCT00438789 | The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol | ||
| NCT05368038 | ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | ||
| NCT07024563 | Study of Ravulizumab in Pediatric Participants With Primary IgAN | ||
| NCT06677138 | PK Study of Gefurulimab SC in Healthy Chinese Adult Participants | ||
| NCT04730804 | A Study of ALXN1830 in Healthy Adult Participants | ||
| NCT03661528 | Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor | ||
| NCT03580941 | Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy | ||
| NCT03551743 | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4) | ||
| NCT01194804 | E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients | ||
| NCT03574506 | Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series | ||
| NCT01205152 | Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP) | ||
| NCT04557735 | Study of Ravulizumab in Pediatric Participants With HSCT-TMA | ||
| NCT04189315 | Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease | ||
| NCT02207725 | A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban | ||
| NCT02596100 | A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations | ||
| NCT04304144 | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | ||
| NCT04469465 | Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) | ||
| NCT06173596 | A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults | ||
| NCT05751642 | Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants | ||
| NCT01403389 | A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant | ||
| NCT05396742 | Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers | ||
| NCT01522170 | aHUS Observational Long Term Follow-Up | ||
| NCT01671956 | Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis | ||
| NCT04233073 | Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery | ||
| NCT03759366 | A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) | ||
| NCT00742859 | Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin | ||
| NCT04889391 | Study of Radiolabeled Danicopan in Healthy Male Participants | ||
| NCT02324049 | Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB) | ||
| NCT02987504 | Study of Samalizumab in Patients With Advanced Cancer | ||
| NCT05239221 | AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism | ||
| NCT04512235 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | ||
| NCT04622046 | A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM | ||
| NCT00984113 | Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment | ||
| NCT00485576 | Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma | ||
| NCT02293408 | Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB | ||
| NCT03346083 | Study Evaluating Betrixaban in Pediatric Participants | ||
| NCT00935883 | Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) | ||
| NCT04752566 | A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome | ||
| NCT00312039 | Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation | ||
| NCT06312644 | Study of Ultomiris® (Ravulizumab) Safety in Pregnancy | ||
| NCT04195763 | Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa) | ||
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | ||
| NCT04609670 | Study of Radiolabeled ALXN2050 in Healthy Adult Males | ||
| NCT03218241 | Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote | ||
| NCT03131219 | Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS) |
